ArticleJournal of orthopaedic surgery and research2025
Epimedium Brevicornu and Curculigo orchioides inhibit osteoclast autophagy by degrading the level of miRNA-199 to regulate the mTOR signaling pathway.
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Systematic Chemical Profiling and Quality Evaluation Framework for Essential Oil Derived fromACS omega · 2026Article
- The N-butanol extract of modified Yanghe decoction alleviates ferroptosis in bone marrow mesenchymal stem cells in glucocorticoid-induced osteoporosis by activating the HIF-1α/GPX4 signaling pathway.Journal of orthopaedic surgery and research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveTo investigate the effect and mechanism of Epimedium brevicornu Maxim. and Curculigo orchioides Gaertn. (EBCO) on miRNA-199 expression in osteoclasts.
methodsEBCO-containing and blank serum was drawn from Wistar rats received EBCO (12 g/kg/d) or the same volume of dH
resultsCompared with the control group, EBCO-containing serum significantly (P < 0.05) decreased the level of miRNA-199 in osteoclasts, increased Mtor mRNA level. The relative fluorescence level was significantly (P < 0.01) decreased after co-transfection of miRNA-199 mimics and MTOR-3'UTR-WT compared to NC-mimics group. EBCO-containing serum reduced cell viability and ROS level, suppressed light chain 3 (LC3)-II/LC3-I and Beclin-1, enhanced phosphorylated mTOR, mTOR and phosphorylated p70S6 kinase (p-p70S6K) proteins expression.
conclusionsEBCO delays the progression of osteoporosis by reducing miRNA-199 in osteoclasts to regulate mTOR signaling and inhibit autophagy. Further research is needed to explore new avenues of clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.